Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Refractory Acute Myeloid Leukemia-Pipeline Review, H1 2015

Refractory Acute Myeloid Leukemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Refractory Acute Myeloid Leukemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Refractory Acute Myeloid Leukemia-Pipeline Review, H1 2015', provides an overview of the Refractory Acute Myeloid Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Refractory Acute Myeloid Leukemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Refractory Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Refractory Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Refractory Acute Myeloid Leukemia Overview 9

Therapeutics Development 10

Pipeline Products for Refractory Acute Myeloid Leukemia-Overview 10

Pipeline Products for Refractory Acute Myeloid Leukemia-Comparative Analysis 11

Refractory Acute Myeloid Leukemia-Therapeutics under Development by Companies 12

Refractory Acute Myeloid Leukemia-Therapeutics under Investigation by Universities/Institutes 17

Refractory Acute Myeloid Leukemia-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Refractory Acute Myeloid Leukemia-Products under Development by Companies 21

Refractory Acute Myeloid Leukemia-Products under Investigation by Universities/Institutes 26

Refractory Acute Myeloid Leukemia-Companies Involved in Therapeutics Development 27

4SC AG 27

AbbVie Inc. 28

Actinium Pharmaceuticals, Inc. 29

Agios Pharmaceuticals, Inc. 30

Amgen Inc. 31

Arog Pharmaceuticals, Inc. 32

Array BioPharma Inc. 33

Astellas Pharma Inc. 34

Astex Pharmaceuticals, Inc. 35

AstraZeneca Plc 36

AVEO Pharmaceuticals, Inc. 37

Boehringer Ingelheim GmbH 38

Bristol-Myers Squibb Company 39

Calithera Biosciences, Inc. 40

Celgene Corporation 41

Conkwest, Inc. 42

Cornerstone Pharmaceuticals, Inc. 43

CTI BioPharma Corp. 44

Daiichi Sankyo Company, Limited 45

Eisai Co., Ltd. 46

EpiZyme, Inc. 47

Exelixis, Inc. 48

F. Hoffmann-La Roche Ltd. 49

Fujifilm Corporation 50

GlaxoSmithKline Plc 51

Igenica Biotherapeutics, Inc. 52

Incyte Corporation 53

Jiangsu Hansoh Pharmaceutical Co., Ltd. 54

JW Pharmaceutical Corporation 55

Karyopharm Therapeutics, Inc. 56

Kyowa Hakko Kirin Co., Ltd. 57

Les Laboratoires Servier SAS 58

MacroGenics, Inc. 59

Merck & Co., Inc. 60

Millennium Pharmaceuticals, Inc. 61

Novartis AG 62

Otsuka Holdings Co., Ltd. 63

Oxford BioTherapeutics Ltd 64

Pharma Mar, S.A. 65

Pharmacyclics, Inc. 66

Plexxikon Inc. 67

Polaris Pharmaceuticals, Inc. 68

Seattle Genetics, Inc. 69

SpectraMab GmbH 70

Sunesis Pharmaceuticals, Inc. 71

Synta Pharmaceuticals Corp. 72

TaiGen Biotechnology Co., Ltd. 73

Threshold Pharmaceuticals, Inc. 74

Tolero Pharmaceuticals, Inc. 75

Verastem, Inc. 76

Refractory Acute Myeloid Leukemia-Therapeutics Assessment 77

Assessment by Monotherapy Products 77

Assessment by Combination Products 78

Assessment by Target 79

Assessment by Mechanism of Action 84

Assessment by Route of Administration 88

Assessment by Molecule Type 90

Drug Profiles 92

4SC-202-Drug Profile 92

AG-120-Drug Profile 94

alvocidib hydrochloride-Drug Profile 96

AMG-232-Drug Profile 97

AT-9283-Drug Profile 98

BI-836858-Drug Profile 100

binimetinib-Drug Profile 101

bortezomib-Drug Profile 106

brentuximab vedotin-Drug Profile 112

burixafor-Drug Profile 118

cabozantinib s-malate-Drug Profile 120

cafusertib hydrochloride-Drug Profile 123

CB-839-Drug Profile 124

CC-90007-Drug Profile 126

Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia-Drug Profile 129

Cell Therapy to Target CD33 for Acute Myeloid Leukemia-Drug Profile 130

Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies-Drug Profile 131

CPI-613-Drug Profile 132

crenolanib besylate-Drug Profile 134

CST-101-Drug Profile 136

CWP-291-Drug Profile 138

DFP-10917-Drug Profile 140

DS-3032-Drug Profile 141

E-6201-Drug Profile 142

elesclomol-Drug Profile 144

eltrombopag olamine-Drug Profile 146

EPZ-5676-Drug Profile 149

erlotinib hydrochloride-Drug Profile 151

evofosfamide-Drug Profile 154

FF-10501-Drug Profile 162

ficlatuzumab-Drug Profile 163

FLX-925-Drug Profile 166

gilteritinib fumarate-Drug Profile 167

GO-2032c-Drug Profile 168

GSK-2879552-Drug Profile 170

GSK-525762-Drug Profile 171

huCART19-Drug Profile 172

ibrutinib-Drug Profile 173

IGN-523-Drug Profile 180

ilorasertib-Drug Profile 181

imatinib mesylate-Drug Profile 183

indisulam-Drug Profile 185

Iomab-B-Drug Profile 187

KHK-2823-Drug Profile 189

lenalidomide-Drug Profile 190

lirilumab-Drug Profile 195

lurbinectedin-Drug Profile 197

MGD-006-Drug Profile 200

midostaurin-Drug Profile 201

MK-2206-Drug Profile 203

OPB-51602-Drug Profile 206

Oshadi D + Oshadi R-Drug Profile 208

OX-001-Drug Profile 209

pegargiminase-Drug Profile 210

PIM-447-Drug Profile 213

PLX-3397-Drug Profile 214

quizartinib dihydrochloride-Drug Profile 216

RG-7775-Drug Profile 219

ruxolitinib phosphate-Drug Profile 220

S-055746-Drug Profile 225

selinexor-Drug Profile 226

selumetinib sulfate-Drug Profile 231

TAK-659-Drug Profile 234

temozolomide-Drug Profile 235

TEN-010-Drug Profile 237

tigecycline-Drug Profile 238

tosedostat-Drug Profile 239

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 241

Triplebody 19x16x19-Drug Profile 243

ulocuplumab-Drug Profile 244

venetoclax-Drug Profile 246

vorinostat-Drug Profile 249

vosaroxin-Drug Profile 253

VS-4718-Drug Profile 255

Refractory Acute Myeloid Leukemia-Recent Pipeline Updates 256

Refractory Acute Myeloid Leukemia-Dormant Projects 410

Refractory Acute Myeloid Leukemia-Discontinued Products 412

Refractory Acute Myeloid Leukemia-Product Development Milestones 413

Featured News & Press Releases 413

Appendix 424

Methodology 424

Coverage 424

Secondary Research 424

Primary Research 424

Expert Panel Validation 424

Contact Us 424

Disclaimer 425

List of Tables

Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2015 16

Number of Products under Development for Refractory Acute Myeloid Leukemia-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 19

Number of Products under Development by Companies, H1 2015 (Contd..1) 20

Number of Products under Development by Companies, H1 2015 (Contd..2) 21

Number of Products under Development by Companies, H1 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Development by Companies, H1 2015 (Contd..4) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Refractory Acute Myeloid Leukemia-Pipeline by 4SC AG, H1 2015 33

Refractory Acute Myeloid Leukemia-Pipeline by AbbVie Inc., H1 2015 34

Refractory Acute Myeloid Leukemia-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 35

Refractory Acute Myeloid Leukemia-Pipeline by Agios Pharmaceuticals, Inc., H1 2015 36

Refractory Acute Myeloid Leukemia-Pipeline by Amgen Inc., H1 2015 37

Refractory Acute Myeloid Leukemia-Pipeline by Arog Pharmaceuticals, Inc., H1 2015 38

Refractory Acute Myeloid Leukemia-Pipeline by Array BioPharma Inc., H1 2015 39

Refractory Acute Myeloid Leukemia-Pipeline by Astellas Pharma Inc., H1 2015 40

Refractory Acute Myeloid Leukemia-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 41

Refractory Acute Myeloid Leukemia-Pipeline by AstraZeneca Plc, H1 2015 42

Refractory Acute Myeloid Leukemia-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 43

Refractory Acute Myeloid Leukemia-Pipeline by Boehringer Ingelheim GmbH, H1 2015 44

Refractory Acute Myeloid Leukemia-Pipeline by Bristol-Myers Squibb Company, H1 2015 45

Refractory Acute Myeloid Leukemia-Pipeline by Calithera Biosciences, Inc., H1 2015 46

Refractory Acute Myeloid Leukemia-Pipeline by Celgene Corporation, H1 2015 47

Refractory Acute Myeloid Leukemia-Pipeline by Conkwest, Inc., H1 2015 48

Refractory Acute Myeloid Leukemia-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 49

Refractory Acute Myeloid Leukemia-Pipeline by CTI BioPharma Corp., H1 2015 50

Refractory Acute Myeloid Leukemia-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 51

Refractory Acute Myeloid Leukemia-Pipeline by Eisai Co., Ltd., H1 2015 52

Refractory Acute Myeloid Leukemia-Pipeline by EpiZyme, Inc., H1 2015 53

Refractory Acute Myeloid Leukemia-Pipeline by Exelixis, Inc., H1 2015 54

Refractory Acute Myeloid Leukemia-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55

Refractory Acute Myeloid Leukemia-Pipeline by Fujifilm Corporation, H1 2015 56

Refractory Acute Myeloid Leukemia-Pipeline by GlaxoSmithKline Plc, H1 2015 57

Refractory Acute Myeloid Leukemia-Pipeline by Igenica Biotherapeutics, Inc., H1 2015 58

Refractory Acute Myeloid Leukemia-Pipeline by Incyte Corporation, H1 2015 59

Refractory Acute Myeloid Leukemia-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 60

Refractory Acute Myeloid Leukemia-Pipeline by JW Pharmaceutical Corporation, H1 2015 61

Refractory Acute Myeloid Leukemia-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 62

Refractory Acute Myeloid Leukemia-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 63

Refractory Acute Myeloid Leukemia-Pipeline by Les Laboratoires Servier SAS, H1 2015 64

Refractory Acute Myeloid Leukemia-Pipeline by MacroGenics, Inc., H1 2015 65

Refractory Acute Myeloid Leukemia-Pipeline by Merck & Co., Inc., H1 2015 66

Refractory Acute Myeloid Leukemia-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 67

Refractory Acute Myeloid Leukemia-Pipeline by Novartis AG, H1 2015 68

Refractory Acute Myeloid Leukemia-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 69

Refractory Acute Myeloid Leukemia-Pipeline by Oxford BioTherapeutics Ltd, H1 2015 70

Refractory Acute Myeloid Leukemia-Pipeline by Pharma Mar, S.A., H1 2015 71

Refractory Acute Myeloid Leukemia-Pipeline by Pharmacyclics, Inc., H1 2015 72

Refractory Acute Myeloid Leukemia-Pipeline by Plexxikon Inc., H1 2015 73

Refractory Acute Myeloid Leukemia-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 74

Refractory Acute Myeloid Leukemia-Pipeline by Seattle Genetics, Inc., H1 2015 75

Refractory Acute Myeloid Leukemia-Pipeline by SpectraMab GmbH, H1 2015 76

Refractory Acute Myeloid Leukemia-Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 77

Refractory Acute Myeloid Leukemia-Pipeline by Synta Pharmaceuticals Corp., H1 2015 78

Refractory Acute Myeloid Leukemia-Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 79

Refractory Acute Myeloid Leukemia-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 80

Refractory Acute Myeloid Leukemia-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 81

Refractory Acute Myeloid Leukemia-Pipeline by Verastem, Inc., H1 2015 82

Assessment by Monotherapy Products, H1 2015 83

Assessment by Combination Products, H1 2015 84

Number of Products by Stage and Target, H1 2015 86

Number of Products by Stage and Mechanism of Action, H1 2015 91

Number of Products by Stage and Route of Administration, H1 2015 95

Number of Products by Stage and Molecule Type, H1 2015 97

Refractory Acute Myeloid Leukemia Therapeutics-Recent Pipeline Updates, H1 2015 262

Refractory Acute Myeloid Leukemia-Dormant Projects, H1 2015 416

Refractory Acute Myeloid Leukemia-Dormant Projects (Contd..1), H1 2015 417

Refractory Acute Myeloid Leukemia-Discontinued Products, H1 2015 418

List of Figures

Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2015 16

Number of Products under Development for Refractory Acute Myeloid Leukemia-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 25

Assessment by Monotherapy Products, H1 2015 83

Number of Products by Top 10 Targets, H1 2015 85

Number of Products by Stage and Top 10 Targets, H1 2015 85

Number of Products by Top 10 Mechanism of Actions, H1 2015 90

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 90

Number of Products by Top 10 Routes of Administration, H1 2015 94

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 94

Number of Products by Top 10 Molecule Types, H1 2015 96

Number of Products by Stage and Top 10 Molecule Types, H1 2015 96

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Amgen Inc.

Arog Pharmaceuticals, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Conkwest, Inc.

Cornerstone Pharmaceuticals, Inc.

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

EpiZyme, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Fujifilm Corporation

GlaxoSmithKline Plc

Igenica Biotherapeutics, Inc.

Incyte Corporation

Jiangsu Hansoh Pharmaceutical Co., Ltd.

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

MacroGenics, Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Novartis AG

Otsuka Holdings Co., Ltd.

Oxford BioTherapeutics Ltd

Pharma Mar, S.A.

Pharmacyclics, Inc.

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Seattle Genetics, Inc.

SpectraMab GmbH

Sunesis Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

TaiGen Biotechnology Co., Ltd.

Threshold Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

Verastem, Inc.

Refractory Acute Myeloid Leukemia Therapeutic Products under Development, Key Players in Refractory Acute Myeloid Leukemia Therapeutics, Refractory Acute Myeloid Leukemia Pipeline Overview, Refractory Acute Myeloid Leukemia Pipeline, Refractory Acute Myeloid Leukemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com